Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11780837 CXCR4 inhibitors and uses thereof

Patent 11780837 was granted and assigned to X4 Pharmaceuticals on October, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent attributes

Patent Applicant

X4 Pharmaceuticals

Current Assignee

X4 Pharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

Patent Inventor Names

Elyse Marie Josee Bourque

Renato Skerlj

Date of Patent

October 10, 2023

Patent Application Number

17654722

Date Filed

March 14, 2022

Patent Citations

US Patent 7354932 Chemokine receptor binding heterocyclic compounds with enhanced efficacy

US Patent 7354934 Chemokine receptor binding heterocyclic compounds with enhanced efficacy

US Patent 7390799 Apoptosis promoters

US Patent 7452994 Synthesis of enantiomerically pure amino-substituted fused bicyclic rings

US Patent 7491544 Chiral piperidine and quinucledine ligands

US Patent 7501518 Methods of making 2,6-diaryl piperidine derivatives

US Patent 7550484 Chemokine receptor binding heterocyclic compounds with enhanced efficacy

US Patent 7592351 Substituted imidazo[1,2-a]pyridine compounds and pharmaceutical preparations containing substituted imidazo[1,2-a]pyridine compounds

...

Patent Primary Examiner

Joseph R Kosack

Patent abstract

The present invention provides compounds, compositions thereof, and methods of using the same.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11780837 CXCR4 inhibitors and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool